BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20700740)

  • 1. Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer.
    Lu YS; Chen DR; Tseng LM; Yeh DC; Chen ST; Hsieh CM; Wang HC; Yeh HT; Kuo SH; Huang CS
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1257-63. PubMed ID: 20700740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
    Lebowitz PF; Eng-Wong J; Swain SM; Berman A; Merino MJ; Chow CK; Venzon D; Zia F; Danforth D; Liu E; Zujewski J
    Clin Cancer Res; 2004 Oct; 10(20):6764-9. PubMed ID: 15501952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
    Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
    Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
    Polyzos A; Felekouras E; Karatzas T; Griniatsos J; Dimitroulis D; Polyzos K; Kontzoglou K; Mantas D; Karavokyros J; Nikiteas N; Tsavaris N; Syrigos K; Vafiadis I
    Anticancer Res; 2012 Sep; 32(9):4151-6. PubMed ID: 22993377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
    von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
    J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer.
    Manga GP; Shahi PK; Ureña MM; Pereira RQ; Plaza MI; Peron YI; Val RG; Carrión JB; Cañón EP; Alfonso PG
    Breast Cancer; 2010 Jul; 17(3):205-11. PubMed ID: 19551465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.
    Greil R; Moik M; Reitsamer R; Ressler S; Stoll M; Namberger K; Menzel C; Mlineritsch B
    Eur J Surg Oncol; 2009 Oct; 35(10):1048-54. PubMed ID: 19250795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer.
    Sym SJ; Chang HM; Ryu MH; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Ann Surg Oncol; 2010 Apr; 17(4):1024-32. PubMed ID: 19941081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
    Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
    Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
    Michalaki V; Fotiou S; Gennatas S; Gennatas C
    Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer.
    Kang YK; Ryu MH; Yoo C; Chang HM; Yook JH; Oh ST; Kim BS; Kim TW
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1435-43. PubMed ID: 20811894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer.
    Villman K; Ohd JF; Lidbrink E; Malmberg L; Lindh B; Blomqvist C; Nordgren H; Bergh J; Bergström D; Ahlgren J
    Eur J Cancer; 2007 May; 43(7):1153-60. PubMed ID: 17398088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma.
    Venturini M; Durando A; Garrone O; Colozza MA; Contu A; Stevani I; Genta F; Bighin C; Lambiase A; Del Mastro L
    Cancer; 2003 Mar; 97(5):1174-80. PubMed ID: 12599222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.
    Ramaswamy B; Povoski SP; Rhoades C; Allen J; Hauger M; Young D; Burak W; Farrar W; Yee L; Kendra K; Somasundaram S; Orlowski RZ; Shapiro CL
    Breast Cancer Res Treat; 2005 Sep; 93(1):67-74. PubMed ID: 16184461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
    Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
    Wardley AM; Pivot X; Morales-Vasquez F; Zetina LM; de Fátima Dias Gaui M; Reyes DO; Jassem J; Barton C; Button P; Hersberger V; Torres AA
    J Clin Oncol; 2010 Feb; 28(6):976-83. PubMed ID: 20038734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-labeled phase II trial of docetaxel in combination with cisplatin as first-line cytotoxic therapy for anthracycline-naive patients with metastatic breast cancer.
    Lin YC; Chang HK; Shen WC; Chen JS; Wang HM
    Anticancer Drugs; 2007 Nov; 18(10):1213-9. PubMed ID: 17893523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.